Cargando…

Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review

Immune checkpoint inhibitors (ICIs) have substantially changed the treatment of a variety of malignant tumors. With the increasing of their usage, the unique immune-mediated toxicity profile of ICIs has become apparent. We report a case of esophageal squamous cell carcinoma in a patient who received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Jing, Li, Dan, Yang, Peidan, Xu, Kunyan, Wang, Yingnan, Li, Qian, Liu, Jiang, Du, Wenli, Zhang, Fengbin, Feng, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761813/ https://www.ncbi.nlm.nih.gov/pubmed/35047395 http://dx.doi.org/10.3389/fonc.2021.778185

Ejemplares similares

Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021)

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021)

Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
por: Ünlütürk, Zeynep, et al.
Publicado: (2023)

Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma
por: Virgen, Cesar A, et al.
Publicado: (2023)

Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis
por: Kufukihara, Kenji, et al.
Publicado: (2019)

Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Todo, Maki, et al.
Publicado: (2019)

Editorial Comment to Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Tomisaki, Ikko
Publicado: (2019)

Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
por: Longinow, Joshua, et al.
Publicado: (2022)

Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
por: Xing, Qian, et al.
Publicado: (2020)

Thymoma-Associated Myasthenia Gravis With Myocarditis
por: Sarwar, Shihab, et al.
Publicado: (2023)

A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient
por: Nakanishi, Shotaro, et al.
Publicado: (2019)

Anti-Kv1.4 Antibody Without Myasthenia Gravis: A Rare Cause of Autoimmune Myocarditis and Myositis
por: Kuyama, Naoto, et al.
Publicado: (2023)

Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
por: Fukasawa, Yoko, et al.
Publicado: (2017)

Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature
por: Yin, Beibei, et al.
Publicado: (2022)

Granulomatous Myositis Associated with Myasthenia Gravis: A Rare Case
por: Iqbal, Shumaila M, et al.
Publicado: (2019)

Acetylcholine receptor binding antibody–associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review
por: Wang, Shengnan, et al.
Publicado: (2022)

Presence of Multiple Autoimmune Antibodies Involved in Concurrent Myositis and Myocarditis and Myasthenia Gravis Without Thymoma: A Case Report
por: Zhou, Zhijian, et al.
Publicado: (2019)

Simultaneous pembrolizumab-induced myasthenia gravis and myocarditis in a patient with metastatic bladder cancer: A case report
por: Takai, Manabu, et al.
Publicado: (2020)

Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis
por: Tang, Mingbo, et al.
Publicado: (2023)

Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
por: Yanase, Takahiro, et al.
Publicado: (2020)

A systematic review of myasthenia gravis complicated with myocarditis
por: Cheng, Wei, et al.
Publicado: (2021)

Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer
por: Hibino, Makoto, et al.
Publicado: (2018)

Giant cell myositis associated with concurrent myasthenia gravis: a case-based review of the literature
por: Scangarello, Frank A, et al.
Publicado: (2021)

Case report: Complex paraneoplastic syndromes in thymoma with nephrotic syndrome, cutaneous amyloidosis, myasthenia gravis, and Morvan’s syndrome
por: Liu, Huiqin, et al.
Publicado: (2022)

Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
por: Luo, Yue-Bei, et al.
Publicado: (2021)

Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life–threatening continuum of neuromuscular and cardiac toxicity
por: Rota, Eugenia, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit
por: Deharo, François, et al.
Publicado: (2022)

Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
por: Huh, So-Young, et al.
Publicado: (2018)

Myositis associated to COVID-19 mimics an acute exacerbation in myasthenia gravis patient
por: De Martino, Antonio, et al.
Publicado: (2021)

Somatic mutations of thymic epithelial tumors with myasthenia gravis
por: Pardini, Eleonora, et al.
Publicado: (2023)

A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil
por: Jespersen, Mette Syberg, et al.
Publicado: (2021)

Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors
por: Schwab, Alfred, et al.
Publicado: (2022)

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade
por: Nelke, Christopher, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review
por: Gao, Loulu, et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
por: Mei, Haoran, et al.
Publicado: (2023)

Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma
por: Fazel, Mahdieh, et al.
Publicado: (2019)

The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma
por: Jeyakumar, Nikeshan, et al.
Publicado: (2020)

Granulomatous Myositis Associated with Extremely Elevated Anti-striated Muscle Antibodies in the Absence of Myasthenia Gravis
por: Meegada, Sreenath, et al.
Publicado: (2020)

Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report
por: Tian, Chia-Yi, et al.
Publicado: (2021)

Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report
por: Saishu, Yumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_82gknceju3ghtgp4cjg1hvqt7a